The Westmead Institute for Medical Research (WIMR) is the lead partner in PrecisionGO. WIMR is a leading institution in genomics and precision medicine, focusing on personalised treatments for various diseases. Our research encompasses cancer, infectious diseases, metabolic disorders, and more. Our Precision Genomics in Intensive Care Medicine Research Group, for instance, investigates the immunology of infectious diseases like sepsis, influenza, and COVID-19, aiming to develop novel diagnostics and therapeutics.WIMR's Genomics Facility is equipped with advanced technologies supporting biomarker discovery and personalised treatments, with impressive world-class capabilities include spatial transcriptomics, single-cell applications, next-generation sequencing, and targeted biomarker detection. These resources facilitate comprehensive genomic analyses, advancing precision medicine initiatives.

Precision medicine is central to WIMR's strategy, as outlined in their Vision 2030 plan. By focusing on an individual's genetic makeup, lifestyle, and environment, WIMR aims to develop tailored treatments, moving away from a one-size-fits-all approach. This strategy enhances patient outcomes and positions WIMR at the forefront of integrating precision medicine into clinical practice.Through these efforts, WIMR is advancing the field of precision medicine, contributing to improved healthcare practices and patient care.

The University of Sydney is at the forefront of genomics and precision medicine research, focusing on understanding the genetic underpinnings of human health to develop effective treatments. This includes cancer genomics, genetic therapies, neurogenetics, newborn screening,ethical and legal considerations, and genomic therapeutics. The University's commitment to integrating genomics into clinical practice is evident through its research areas, through which its researchers aim to uncover the underlying causes of diseases and develop targeted treatments, advancing the field of precision medicine to improve patient outcomes and healthcare practices.

NSW Health Pathology is Australia’s largest public pathology and forensic & analytical science service, proudly employing more than 5,000 staff. NSW Health Pathology performs over 100,000 clinical and scientific investigations each day across its 60 laboratories and 150-plus collection centres.

NSW Health Pathology plays a critical role in ensuring the community has access to the latest advances in research, leading the way in cutting-edge fields such as genomics in the pursuit of personalised medicine. NSW Health Pathology is excited to be a collaborator in the PrecisionGo project and to ensure the research outcomes are translated into service delivery, providing equitable access to the latest tests for the people of NSW.

The Australian e-Health Research Centre (AEHRC), part of CSIRO Health and Biosecurity, is the leading digital health research centre in Australia. The AEHRC undertakes research in areas such as medical imaging, genomics, electronic health data, data collected form health devices and sensors amongst others. The AEHRC has an international reputation in using international health data standards for the collection and analysis of health data. This includes working with the Australian Digital Health Agency on the National Clinical Terminology Service - enabling the collection of data using the SNOMED CT clinical terminology. The AEHRC is also a leader in the use of the Fast Healthcare InteroperableResource (FHIR) standard for the capture and exchange of health information.

Being part of the PrecisionGO project aligns well with AEHRC’s emphasis on world class science, technological innovation and strong industry partnerships. Our research takes a collaborative approach with strong clinical and consumer engagement during projects and our multi- disciplinary team is dedicated to serving the needs of patients, clinicians and health agencies. We work closely with government health departments, universities, hospitals and health services in metropolitan, rural and regional areas to undertake research in e-health, big data, AI/ML, decision support, software development, mobile technologies, health internet of things, digital healthcare services, clinical needs, medical and laboratory workflows and more.

Children’s Medical Research Institute (CMRI) is an independent medical research institute dedicated to improving the health and well-being of children. CMRI’s world leading research focuses on understanding the fundamental genetic causes of diseases, and using this knowledge to develop novel diagnostic tools, therapeutic interventions, and preventative strategies. CMRI’s core areas of expertise are cancer, genomics, gene therapy, neurobiology, embryology and stem cell biology. CMRI is home to internationally recognised programs in gene therapy/viral vector technologies, and a world first cancer proteomics facility called ProCan. These programs are set to deliver major advances in biomedical technologies that will transform healthcare delivery.

Located in the Westmead Health Precinct in Sydney, CMRI is home to more than 130 research staff, including 20 higher degree research students, and is engaged in more than 560 research collaborations worldwide. The institute operates within the framework of the Westmead Research Hub, which brings together various leading research and clinical institutions to foster collaboration and accelerate discovery and translation in health and medical research. With a keen interest in paediatric precision medicine, CMRI is also a founding member of Luminesce Alliance, which conducts basic and translational research in precision medicine in conjunction with the Sydney Children’s Hospital Network and the Children’s Cancer Institute.

The Sydney Children’s Hospitals Network cares for thousands of children each year with one purpose in mind, to help young people live their healthiest lives.

As the largest paediatric health care service in Australia, they incorporate two tertiary paediatric hospitals; The Children's Hospital at Westmead and Sydney Children's Hospital, Randwick; Bear Cottage, the only paediatric hospice in NSW; the statewide paediatric emergency retrieval service, Newborn and Paediatric Emergency Transport Service (NETS) and the Children's Court Clinic, a court assessment service. They also operate paediatric translational research through their research body, Kids Research.

Kids Research has been leading the way for paediatric translational research since 2009, working together with a state-wide network of universities, research institutions and clinical services. They aim to improve the health of sick children through the translation of new discoveries into clinical practice.

AGRF Ltd is a not-for-profit organisation, powering Australian genomics and proteomics through our national network of multi-omic services and expertise. As Australia’s premier omics provider, AGRF is a key contributor to molecular innovation and development, delivering local access to expertise, state-of-the-art technology, and comprehensive support across a broad range of industries including biomedical, health, agriculture, and environmental sectors.

AGRF is proud to support the PrecisionGO project, a collaboration that aligns with our mission to deliver world-class genomic solutions that drive innovation and improve lives.  By partnering with PrecisionGO, AGRF is enhancing its role in the genomics community, providing cutting-edge precision medicine capabilities that will enable faster, more accurate diagnosis and personalised treatments.  Together we are shaping the future of healthcare through innovative genomic technologies.

BD is one of the largest global medical technology companies in the world and is advancing the world of healthTM  by improving medical discovery, diagnostics and the delivery of care.

BD and more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

PrecisionGO objectives to advance medical research and improve health outcomes align with BD’s vision. The inclusion of the BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology and BD SpectralFX™ Technology and the BD Rhapsody™ Single-Cell Analysis System will be key to PrecisionGO as it seeks to accelerate the implementation of precision medicine at the clinical interface in Australia.